Biomedical Microdevices

, 20:88 | Cite as

Combination therapy comprising irreversible electroporation and hydroxycamptothecin loaded electrospun membranes to treat rabbit VX2 subcutaneous cancer

  • Lizhe Wang
  • Jian Chang
  • Yaqin QuEmail author
  • Renna QiuEmail author


Irreversible electroporation (IRE) is a kind of promising cancer treatment technology. However, local recurrence still occurs because of incomplete ablation. The aim of this study was to investigate the combined therapy of IRE and a hydroxycamptothecin loaded electrospun membrane (EM/HCPT) to treat rabbit VX2 subcutaneous cancer. HCPT loaded membranes were developed by electrospinning. Mechanical test and in vitro drug release study of EM/HCPT were performed. 24 rabbits with subcutaneous VX2 tumor were randomly divided into four groups: the control group, the EM/HCPT group, the IRE ablation group, and the IRE + EM/HCPT group. The tumor cells were ablated by IRE first, followed by subcutaneous implantation of EM/HCPT to release HCPT constantly in order to damage the residual cancer cells. The tumor inhibition efficacy was assessed by the tumor real-time monitoring, histological and immunofluorescent analyses, and transmission electron microscopy (TEM) examination. Assessment of the release from EM/HCPT showed that HCPT release lasted for about 7 days. The in vivo antitumor efficacy assessment, histological and immunofluorescent analyses, and TEM examination showed that IRE + EM/HCPT had the best tumor inhibition ability. In addition, the biochemical analyses and hematoxylin and eosin (H&E) staining of normal organs indicated that IRE + EM/HCPT treatment was safe. Our study provided a new concept in cancer treatment and might promote the application of IRE.


Irreversible electroporation Hydroxycamptothecin Electrospun membrane VX2 cancer Combination therapy 



We thank Elixigen Corporation (Huntington Beach, California, USA) for helping in proofreading and editing the English of final manuscript.

Compliance with ethical standards

Conflict of interest

The authors report no declarations of interest.


  1. U. Aggarwal, A.K. Goyal, G. Rath, Development and characterization of the cisplatin loaded nanofibers for the treatment of cervical cancer. Mater. Sci. Eng. C Mater. Biol. Appl. 75, 125–132 (2017)CrossRefGoogle Scholar
  2. R. Cannon, S. Ellis, D. Hayes, G. Narayanan, R.C. Martin 2nd, Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. Eur. J. Surg. Oncol. 107(5), 544–549 (2013)CrossRefGoogle Scholar
  3. W. Cui, X. Li, X. Zhu, G. Yu, S. Zhou, J. Weng, Investigation of drug release and matrix degradation of electrospun poly(DL-lactide) fibers with paracetanol inoculation. Biomacromolecules 7(5), 1623–1629 (2006)CrossRefGoogle Scholar
  4. M. Figini, X. Wang, T. Lyu, Z. Su, D. Procissi, V. Yaghmai, et al., Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging. Am. J. Transl. Res. 9(2), 580–590 (2017)Google Scholar
  5. Y. Guo, Y. Zhao, T. Wang, R. Li, M. Han, Z. Dong, et al., Hydroxycamptothecin Nanorods Prepared by Fluorescently Labeled Oligoethylene Glycols (OEG) Codendrimer: Antitumor Efficacy in Vitro and in Vivo. Bioconjug. Chem. 28(2), 390–399 (2017)CrossRefGoogle Scholar
  6. H. Jiang, Y. Hu, Y. Li, P. Zhao, K. Zhu, W. Chen, A facile technique to prepare biodegradable coaxial electrospun nanofibers for controlled release of bioactive agents. J. Control. Release 108(2–3), 237–243 (2005)CrossRefGoogle Scholar
  7. G. Kourounis, P. Paul Tabet, D. Moris, A. Papalambros, E. Felekouras, F. Georgiades, et al., Irreversible electroporation (Nanoknife(R) treatment) in the field of hepatobiliary surgery: Current status and future perspectives. Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology 22(1), 141–149 (2017)Google Scholar
  8. E.W. Lee, C. Chen, V.E. Prieto, S.M. Dry, C.T. Loh, S.T. Kee, Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 255(2), 426–433 (2010)CrossRefGoogle Scholar
  9. J. Li, Z. Sun, J. Zhang, H. Shao, M.M. Cona, H. Wang, et al., A dual-targeting anticancer approach: soil and seed principle. Radiology 260(3), 799–807 (2011)CrossRefGoogle Scholar
  10. J.N. Li, W.G. Xu, J.J. Chen, D. Li, K. Zhang, T.J. Liu, et al., Highly Bioadhesive Polymer Membrane Continuously Releases Cytostatic and Anti-Inflammatory Drugs for Peritoneal Adhesion Prevention. ACS Biomater Sci. Eng. 4(6), 2026–2036 (2018)CrossRefGoogle Scholar
  11. Z. Liu, H. Li, Y. Fan, Y. Liu, S. Man, P. Yu, et al., Combination treatment with Rhizoma Paridis and Rhizoma Curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in H22 tumor model by increasing the plasma concentration. Biomed. Pharmacother. 83, 627–634 (2016)CrossRefGoogle Scholar
  12. R.C. Martin 2nd, D. Kwon, S. Chalikonda, M. Sellers, E. Kotz, C. Scoggins, et al., Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann. Surg. 262(3), 486–494 (2015) discussion 492–4CrossRefGoogle Scholar
  13. L. Qinglin, X. Wenxiu, Z. Like, Fangluo, C. Gang, H. Ping, A study on the anti-tumor mechanism of total flavonoids from radix tetrastigmae against additional cell line based on COX-2-mediated Wnt/beta-catenin signaling pathway, Oncotarget (2017).Google Scholar
  14. N. Saderi, M. Rajabi, B. Akbari, M. Firouzi, Z. Hassannejad, Fabrication and characterization of gold nanoparticle-doped electrospun PCL/chitosan nanofibrous scaffolds for nerve tissue engineering. J. Mater. Sci. Mater. Med. 29(9) (2018)Google Scholar
  15. O.F. Sarioglu, A. Ozdemir, K. Karaboduk, T. Tekinay, Comparative serum albumin interactions and antitumor effects of Au(III) and Ga(III) ions. J. Trace Elem. Med. Biol. 29, 111–115 (2015)CrossRefGoogle Scholar
  16. S.V. Sudakaran, J.R. Venugopal, G.P. Vijayakumar, S. Abisegapriyan, A.N. Grace, S. Ramakrishna, Sequel of MgO nanoparticles in PLACL nanofibers for anti-cancer therapy in synergy with curcumin/beta-cyclodextrin. Mater. Sci. Eng. C Mater. Biol. Appl. 71, 620–628 (2017)CrossRefGoogle Scholar
  17. J.A. Vogel, E. van Veldhuisen, P. Agnass, J. Crezee, F. Dijk, J. Verheij, et al., Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies. PloS one 11(11), e0166987 (2016)CrossRefGoogle Scholar
  18. H. Wang, J. Feng, G. Liu, B. Chen, Y. Jiang, Q. Xie, In vitro and in vivo anti-tumor efficacy of 10-hydroxycamptothecin polymorphic nanoparticle dispersions: shape- and polymorph-dependent cytotoxicity and delivery of 10-hydroxycamptothecin to cancer cells. Nanomed.: Nanotechnol., Biol. Med. 12(4), 881–891 (2016)CrossRefGoogle Scholar
  19. J.J. Wendler, R. Ganzer, B. Hadaschik, A. Blana, T. Henkel, K.U. Kohrmann, et al., Irreversible electroporation. Current value for focal treatment of prostate cancer. Der Urologe. Ausg. A 54(6), 854–862 (2015)CrossRefGoogle Scholar
  20. C. Zhang, D. Pan, K. Luo, W. She, C. Guo, Y. Yang, et al., Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Adv. Healthc. Mater. 3(8), 1299–1308 (2014)CrossRefGoogle Scholar
  21. M. Zhu, X.A. Lin, X.M. Zha, W.B. Zhou, T.S. Xia, S. Wang, Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor model. PloS one 10(3), e0120303 (2015)CrossRefGoogle Scholar
  22. A. Zimmerman, D. Grand, K.P. Charpentier, Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. Journal of Hepatocellular Carcinoma 4, 49–58 (2017)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The First Hospital of Jilin UniversityJilinChina
  2. 2.China-Japan Union Hospital of Jilin UniversityJilinChina

Personalised recommendations